As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Meningococcal Vaccines Market: By Type: Polysaccharide Vaccine, Conjugate Vaccine, Serogroup B Vaccine; By Age Group: Infants, Children, Adults, Others; By Distribution Channel; Regional Analysis; Historical Market and Forecast (2016-2026); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Meningococcal Vaccines Market Outlook

The global meningococcal vaccines market stood at 172 million doses in 2020. The global meningococcal vaccines market is expected to grow at a healthy pace in the forecast period of 2021-2026.

 

Global Meningococcal Vaccines Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Prevalence of Meningococcal Meningitis to Aid the Market Growth of Meningococcal Vaccines

The market growth of meningococcal vaccines is being driven by the rising prevalence of various types of bacteria that trigger meningococcal meningitis. The most common among them are A, B, C, W, Y, and type X that was lately tracked in Africa. This is aiding the market growth of meningococcal vaccines as the demand for effective meningococcal vaccines is on the rise over the forecast period. The market is further being propelled by the extremely unpredictable dissemination of this bacteria and fluctuating occurrences of the disease over time and across different age groups and geographies, which has resulted in a considerable increase in the frequency of clinical programmes for the development of efficient meningococcal vaccines worldwide. Moreover, several ongoing clinical programmes for the development of meningococcal vaccines at varying stages is further facilitating the market growth globally.

 

Meningococcal Vaccines: Industry Definition and Segmentation

Meningococcal meningitis is a rare and potentially disturbing bacterial infection that affects the brain. Even after the advances in the medical field, the disease has the potential to take the life of the host in a relatively lesser timespan. Meningococcal vaccines are produced as the prevention of meningococcal meningitis.

 

Global Meningococcal Vaccines Market By Age Group

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

On the basis of type, the market is divided into:

  • Polysaccharide Vaccine (MPSV4)
  • Conjugate Vaccine (MCV4)
  • Serogroup B Vaccine (MenB-FHpb/MenB-4C)

Based on age group, the industry can be segmented into:

  • Infants
  • Children
  • Adults
  • Others

By distribution channel, the industry is categorised into:

  • Institutional Sales
  • Retail Sales

These segments are further divided on the basis of type. Institutional sales are divided into hospitals, community clinics, and public health agencies, whereas retail sales are divided into retail pharmacy and online, among others.

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Meningococcal Vaccines Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Initiatives by the Government to Aid the Market Growth of Meningococcal Vaccines

The market growth of meningococcal vaccines is being driven by the rising initiatives like National Immunization Programs (NIPs) by the governments and supported by private non-profit organisations for the development of meningococcal vaccines. Further, the addition of meningococcal vaccines to NIPs with the motive to ascertain vaccine supply affordability and sustainability in public and private sectors has been generating an abundance of opportunities for the manufacturers.

 

Key Industry Players in the Global Meningococcal Vaccines Market

The report gives a detailed analysis of the following key players in the global meningococcal vaccines market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Pfizer Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Incepta Vaccine Ltd. 
  • Others

The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model along with giving a SWOT analysis.

 

REPORT FEATURES DETAILS
Base Year 2020
Historical Period 2016-2020
Forecast Period 2021-2026
Scope of the Report Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Age Group, Distribution Channel, Region
Breakup by Type Polysaccharide Vaccine (MPSV4), Conjugate Vaccine (MCV4), Serogroup B Vaccine (MenB-FHpb/MenB-4C)
Breakup by Age Group Infants, Children, Adults, Others
Breakup by Distribution Channel Institutional Sales, Retail Sales
Breakup by Region North America, Latin America, Europe, Middle East and Africa, Asia Pacific
Market Dynamics SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand
Competitive Landscape Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications
Companies Covered Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, Incepta Vaccine Ltd., Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Meningococcal Vaccines Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Meningococcal Vaccines Historical Market (2016-2020) 
    8.3    Global Meningococcal Vaccines Market Forecast (2021-2026)
    8.4    Global Meningococcal Vaccines Market by Type
        8.4.1    Polysaccharide Vaccine (MPSV4)
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2016-2020)
            8.4.1.3    Forecast Trend (2021-2026)
        8.4.2    Conjugate Vaccine (MCV4)
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2016-2020)
            8.4.2.3    Forecast Trend (2021-2026)
        8.4.3    Serogroup B Vaccine (MenB-FHpb/MenB-4C)
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2016-2020)
            8.4.3.3    Forecast Trend (2021-2026)
    8.5    Global Meningococcal Vaccines Market by Age Group
        8.5.1    Infants
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2016-2020)
            8.5.1.3    Forecast Trend (2021-2026)
        8.5.2    Children
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2016-2020)
            8.5.2.3    Forecast Trend (2021-2026)
        8.5.3    Adults
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2016-2020)
            8.5.3.3    Forecast Trend (2021-2026)
        8.5.4    Others
    8.6    Global Meningococcal Vaccines Market by Distribution Channel
        8.6.1    Institutional Sales
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2016-2020)
            8.6.1.3    Forecast Trend (2021-2026)
            8.6.1.4    Breakup by Type
                8.6.1.4.1    Hospitals
                    8.6.1.4.1.1    Market Share
                    8.6.1.4.1.2    Historical Trend (2016-2020)
                    8.6.1.4.1.3    Forecast Trend (2021-2026)
                8.6.1.4.2    Community Clinics
                    8.6.1.4.2.1    Market Share
                    8.6.1.4.2.2    Historical Trend (2016-2020)
                    8.6.1.4.2.3    Forecast Trend (2021-2026)
                8.6.1.4.3    Public Health Agencies
                    8.6.1.4.3.1    Market Share
                    8.6.1.4.3.2    Historical Trend (2016-2020)
                    8.6.1.4.3.3    Forecast Trend (2021-2026)
        8.6.2    Retail Sales
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2016-2020)
            8.6.2.3    Forecast Trend (2021-2026)
            8.6.2.4    Breakup by Type
                8.6.2.4.1    Retail Pharmacy
                    8.6.2.4.1.1    Market Share
                    8.6.2.4.1.2    Historical Trend (2016-2020)
                    8.6.2.4.1.3    Forecast Trend (2021-2026)
                8.6.2.4.2    Online
                    8.6.2.4.2.1    Market Share
                    8.6.2.4.2.2    Historical Trend (2016-2020)
                    8.6.2.4.2.3    Forecast Trend (2021-2026)
                8.6.2.4.3    Others
    8.7    Global Meningococcal Vaccines Market by Region
        8.7.1    Market Share
            8.7.1.1    North America
            8.7.1.2    Europe
            8.7.1.3    Asia Pacific
            8.7.1.4    Latin America
            8.7.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2016-2020)
        9.1.2    Forecast Trend (2021-2026)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2016-2020)
        9.2.2    Forecast Trend (2021-2026)
        9.2.3    Breakup by Country
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2016-2020)
        9.3.2    Forecast Trend (2021-2026)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2016-2020)
        9.4.2    Forecast Trend (2021-2026)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2016-2020)
        9.5.2    Forecast Trend (2021-2026)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Competitive Landscape
    11.1    Market Structure
    11.2    Company Profiles
        11.2.1    Pfizer Inc.
            11.2.1.1    Company Overview
            11.2.1.2    Product Portfolio
            11.2.1.3    Demographic Reach and Achievements
            11.2.1.4    Certifications
        11.2.2    Sanofi SA
            11.2.2.1    Company Overview
            11.2.2.2    Product Portfolio
            11.2.2.3    Demographic Reach and Achievements
            11.2.2.4    Certifications
        11.2.3    GlaxoSmithKline plc
            11.2.3.1    Company Overview
            11.2.3.2    Product Portfolio
            11.2.3.3    Demographic Reach and Achievements
            11.2.3.4    Certifications
        11.2.4    Incepta Vaccine Ltd. 
            11.2.4.1    Company Overview
            11.2.4.2    Product Portfolio
            11.2.4.3    Demographic Reach and Achievements
            11.2.4.4    Certifications
        11.2.5    Others
12    Industry Events and Developments

 

List of Figures and Tables

1.    Global Meningococcal Vaccines Market: Key Industry Highlights, 2016 and 2026
2.    Global Meningococcal Vaccines Historical Market: Breakup by Type (Million Doses), 2016-2020
3.    Global Meningococcal Vaccines Market Forecast: Breakup by Type (Million Doses), 2021-2026
4.    Global Meningococcal Vaccines Historical Market: Breakup by Age Group (Million Doses), 2016-2020
5.    Global Meningococcal Vaccines Market Forecast: Breakup by Age Group (Million Doses), 2021-2026
6.    Global Meningococcal Vaccines Historical Market: Breakup by Distribution Channel (Million Doses), 2016-2020
7.    Global Meningococcal Vaccines Market Forecast: Breakup by Distribution Channel (Million Doses), 2021-2026
8.    Global Meningococcal Vaccines Historical Market: Breakup by Region (Million Doses), 2016-2020
9.    Global Meningococcal Vaccines Market Forecast: Breakup by Region (Million Doses), 2021-2026
10.    North America Meningococcal Vaccines Historical Market: Breakup by Country (Million Doses), 2016-2020
11.    North America Meningococcal Vaccines Market Forecast: Breakup by Country (Million Doses), 2021-2026
12.    Europe Meningococcal Vaccines Historical Market: Breakup by Country (Million Doses), 2016-2020
13.    Europe Meningococcal Vaccines Market Forecast: Breakup by Country (Million Doses), 2021-2026
14.    Asia Pacific Meningococcal Vaccines Historical Market: Breakup by Country (Million Doses), 2016-2020
15.    Asia Pacific Meningococcal Vaccines Market Forecast: Breakup by Country (Million Doses), 2021-2026
16.    Latin America Meningococcal Vaccines Historical Market: Breakup by Country (Million Doses), 2016-2020
17.    Latin America Meningococcal Vaccines Market Forecast: Breakup by Country (Million Doses), 2021-2026
18.    Middle East and Africa Meningococcal Vaccines Historical Market: Breakup by Country (Million Doses), 2016-2020
19.    Middle East and Africa Meningococcal Vaccines Market Forecast: Breakup by Country (Million Doses), 2021-2026
20.    Global Meningococcal Vaccines Market Structure

Key Questions Answered in the Report

In 2020, the global meningococcal vaccines market attained 172 million doses.

The major drivers of the industry, such as rising disposable incomes, increasing population, rising prevalence of the disease, and increasing demand for effective meningococcal vaccines, are expected to aid the market growth.

The key market trend guiding the growth of the industry includes the rise in the initiatives undertaken by the government.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The leading types of meningococcal vaccines in the market are polysaccharide vaccine (MPSV4), conjugate vaccine (MCV4), and serogroup B vaccine (MenB-FHpb/MenB-4C).

The major age groups considered in the market report are infants, children, and adults, among others.

The significant distribution channels in the industry are institutional sales and retail sales.

The major players in the industry are Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, and Incepta Vaccine Ltd., among others.

Analyst Review

The global meningococcal vaccines market attained 172 million doses in 2020, driven by rising prevalence of urinary incontinence among the growing geriatric population. Aided by the technological advancements, the market is expected to witness a healthy growth in the forecast period of 2021-2026.
 
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on type, the market is segmented into polysaccharide vaccine (MPSV4), conjugate vaccine (MCV4), and serogroup B vaccine (MenB-FHpb/MenB-4C). By age group, the industry is divided into infants, children, and adults, among others. On the basis of distribution channel, the market is segmented into institutional sales and retail sales. The major regional markets for meningococcal vaccines are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, and Incepta Vaccine Ltd., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER